Self-Reliance in the 21st Century
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Recognized as Outstanding ... MarketWatch (press release) Emergent's marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the US Food and Drug Administration for the prevention ... |
Emergent BioSolutions Reports Financial Results for Full Year 2009 MarketWatch (press release) The 2009 performance was primarily driven by sales of BioThrax(R) (Anthrax Vaccine Adsorbed), the company's FDA licensed vaccine for the prevention of ... Emergent BioSolutions revenue up 50% Emergent Q4 profit beats Street; shares rise Emergent BioSolutions shares rise after 4Q report |
PharmAthene wins extension on anthrax vaccine contract Washington Post ... said on Tuesday that the US Department of Health and Human Services has expanded a development contract for the company's anthrax vaccine, SparVax. ... Firm Receives up to $78M More for Anthrax Vaccine Research Drug stocks advance; PharmAthene retreats PharmAthene to continue work on vaccine |
 FOXNews | $150M Anthrax Vaccine Contract Goes to Firm With Close Dem Party Ties FOXNews The Obama administration has steered up to $150 million in federal funding for the development and production of an anthrax vaccine to a ... |
Human Genome Sciences teams with Swedish firm on research Washington Business Journal Human Genome Sciences (NASDAQ: HGSI), which last year had its first-ever product sales with its anthrax vaccine to the federal government and reported ... |
